Key facts
- LeadingTac’s last known valuation is $8.5M (Nov 2019).
- It has raised $63.8M; the latest was Early Stage VC ($31.1M) in Dec 2025.
- Notable investors include CDH Investments, YuanBio Venture Capital, Lapam Capital, Hankang Capital, Zhangjiang Group — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for LeadingTac
- ·The full record, as it builds
Funding rounds
No funding rounds for LeadingTac are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LeadingTac
Developer of small-molecule innovative therapeutics intended for the treatment of autoimmune and tumor diseases. The company offers research platforms and drug candidates leveraging targeted protein degradation technologies, proprietary intracellular and extracellular protein ubiquitination systems, modular small molecule compounds with E3 ligase recruitment, secure clinical trial progression infrastructure, and global intellectual property coverage, enabling biopharma developers, clinicians, and research collaborators to advance first in class therapeutic candidates through preclinical and clinical stages with enhanced target specificity and streamlined development pathways.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2019
- Employees
- 30
- Website
- leadingtac.com/
- Ownership
- Privately Held (backing)
LeadingTac doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LeadingTac shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LeadingTac in its N-PORT filings yet. We sweep new filings monthly.